Loading…
Association Between Metabolic Syndrome and Mild Parkinsonian Signs Progression in the Elderly
This study investigated the impact of metabolic syndrome on the progression from mild parkinsonian signs (MPS) to Parkinson's disease (PD). A total of 1,563 participants with MPS completed 6 years of follow-up. The diagnosis of metabolic syndrome was made according to Adult Treatment Panel III...
Saved in:
Published in: | Frontiers in aging neuroscience 2021-10, Vol.13, p.722836-722836 |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c493t-e8ba638e101205dc084b81f0010352b03812dde043f8c80f88528266a3dbd0f43 |
---|---|
cites | cdi_FETCH-LOGICAL-c493t-e8ba638e101205dc084b81f0010352b03812dde043f8c80f88528266a3dbd0f43 |
container_end_page | 722836 |
container_issue | |
container_start_page | 722836 |
container_title | Frontiers in aging neuroscience |
container_volume | 13 |
creator | Peng, Zeyan Zhou, Rui Liu, Dong Cui, Min Yu, Ke Yang, Hai Li, Ling Liu, Juan Chen, Yang Hong, Wenjuan Huang, Jie Wang, Congguo Ma, Jingjing Zhou, Huadong |
description | This study investigated the impact of metabolic syndrome on the progression from mild parkinsonian signs (MPS) to Parkinson's disease (PD).
A total of 1,563 participants with MPS completed 6 years of follow-up. The diagnosis of metabolic syndrome was made according to Adult Treatment Panel III of the National Cholesterol Education Program. The evaluations of MPS and PD were based on the motor portion of the Unified Parkinson's Disease Rating Scale. Cox proportional hazard models were used to identify the association between metabolic syndrome and PD conversion.
Of the 1,563 participants, 482 (30.8%) with MPS developed PD at the end of the follow-up. Metabolic syndrome (HR: 1.69, 95% CI: 1.29-2.03) was associated with the risk of PD conversion. Metabolic syndrome was associated with the progression of bradykinesia (HR: 1.85, 95% CI: 1.43-2.34), rigidity (HR: 1.36, 95% CI: 1.19-1.57), tremor (HR: 1.98, 95% CI: 1.73-2.32), and gait/balance impairment (HR: 1.66, 95% CI: 1.25-2.11). The effect of metabolic syndrome on the progression of bradykinesia and tremor was nearly two fold. Participants treated for two or three to four components of metabolic syndrome, including high blood pressure, high fasting plasma glucose, hypertriglyceridemia, and low HDL-C, had a lower risk of PD conversion.
Metabolic syndrome increased the risk of progression from MPS to PD. Participants treated for two or more components of metabolic syndrome had a lower risk of PD conversion. |
doi_str_mv | 10.3389/fnagi.2021.722836 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_dc6df4159cdf4f9abba7150330713599</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_dc6df4159cdf4f9abba7150330713599</doaj_id><sourcerecordid>2578262502</sourcerecordid><originalsourceid>FETCH-LOGICAL-c493t-e8ba638e101205dc084b81f0010352b03812dde043f8c80f88528266a3dbd0f43</originalsourceid><addsrcrecordid>eNpdksFO3DAQhqOqVUGUB-ilstRLL7u1PXEyuVSiCFokEEi0x8py7EnwNmtTO9tq356EpQjwZSz7n88z478o3gu-BMDmcxdM75eSS7GspUSoXhX7oqpgUUKlXj_Z7xWHOa_4tAA4V_i22IOyUohQ7xe_jnKO1pvRx8C-0viPKLALGk0bB2_Z9Ta4FNfETHDswg-OXZn024ccgzeBXfs-ZHaVYp8o5xnhAxtviJ0MjtKwfVe86cyQ6fAhHhQ_T09-HH9fnF9-Ozs-Ol_YsoFxQdiaCpAEF5IrZzmWLYqOc8FByZYDCukc8RI6tMg7RCVRVpUB1zrelXBQnO24LpqVvk1-bdJWR-P1_UFMvTZp9HYg7WzlulKoxk6ha0zbmlqoeTS1ANU0E-vLjnW7adfkLIUxmeEZ9PlN8De6j381KoEC52I-PQBS_LOhPOq1z5aGwQSKm6ylQgApaj6_9fGFdBU3KUyjmlT11KJUXE4qsVPZFHNO1D0WI7ievaDvvaBnL-idF6acD0-7eMz4__NwB66nsBA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2578262502</pqid></control><display><type>article</type><title>Association Between Metabolic Syndrome and Mild Parkinsonian Signs Progression in the Elderly</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Peng, Zeyan ; Zhou, Rui ; Liu, Dong ; Cui, Min ; Yu, Ke ; Yang, Hai ; Li, Ling ; Liu, Juan ; Chen, Yang ; Hong, Wenjuan ; Huang, Jie ; Wang, Congguo ; Ma, Jingjing ; Zhou, Huadong</creator><creatorcontrib>Peng, Zeyan ; Zhou, Rui ; Liu, Dong ; Cui, Min ; Yu, Ke ; Yang, Hai ; Li, Ling ; Liu, Juan ; Chen, Yang ; Hong, Wenjuan ; Huang, Jie ; Wang, Congguo ; Ma, Jingjing ; Zhou, Huadong</creatorcontrib><description>This study investigated the impact of metabolic syndrome on the progression from mild parkinsonian signs (MPS) to Parkinson's disease (PD).
A total of 1,563 participants with MPS completed 6 years of follow-up. The diagnosis of metabolic syndrome was made according to Adult Treatment Panel III of the National Cholesterol Education Program. The evaluations of MPS and PD were based on the motor portion of the Unified Parkinson's Disease Rating Scale. Cox proportional hazard models were used to identify the association between metabolic syndrome and PD conversion.
Of the 1,563 participants, 482 (30.8%) with MPS developed PD at the end of the follow-up. Metabolic syndrome (HR: 1.69, 95% CI: 1.29-2.03) was associated with the risk of PD conversion. Metabolic syndrome was associated with the progression of bradykinesia (HR: 1.85, 95% CI: 1.43-2.34), rigidity (HR: 1.36, 95% CI: 1.19-1.57), tremor (HR: 1.98, 95% CI: 1.73-2.32), and gait/balance impairment (HR: 1.66, 95% CI: 1.25-2.11). The effect of metabolic syndrome on the progression of bradykinesia and tremor was nearly two fold. Participants treated for two or three to four components of metabolic syndrome, including high blood pressure, high fasting plasma glucose, hypertriglyceridemia, and low HDL-C, had a lower risk of PD conversion.
Metabolic syndrome increased the risk of progression from MPS to PD. Participants treated for two or more components of metabolic syndrome had a lower risk of PD conversion.</description><identifier>ISSN: 1663-4365</identifier><identifier>EISSN: 1663-4365</identifier><identifier>DOI: 10.3389/fnagi.2021.722836</identifier><identifier>PMID: 34658837</identifier><language>eng</language><publisher>Switzerland: Frontiers Research Foundation</publisher><subject>Aging ; Alzheimer's disease ; Balance ; Basal ganglia ; Blood pressure ; Body mass index ; Cardiovascular disease ; Carotid arteries ; Central nervous system diseases ; Cholesterol ; Cognitive ability ; elderly ; Fasting ; Gait ; Geriatric psychology ; Glucose ; Head injuries ; High density lipoprotein ; Hospitals ; Hypertension ; Hypertriglyceridemia ; Metabolic syndrome ; mild parkinsonian signs ; Movement disorders ; Neurodegenerative diseases ; Neuroscience ; Obesity ; Older people ; Parkinson's disease ; progression ; Risk factors ; Tremor ; Womens health</subject><ispartof>Frontiers in aging neuroscience, 2021-10, Vol.13, p.722836-722836</ispartof><rights>Copyright © 2021 Peng, Zhou, Liu, Cui, Yu, Yang, Li, Liu, Chen, Hong, Huang, Wang, Ma and Zhou.</rights><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2021 Peng, Zhou, Liu, Cui, Yu, Yang, Li, Liu, Chen, Hong, Huang, Wang, Ma and Zhou. 2021 Peng, Zhou, Liu, Cui, Yu, Yang, Li, Liu, Chen, Hong, Huang, Wang, Ma and Zhou</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c493t-e8ba638e101205dc084b81f0010352b03812dde043f8c80f88528266a3dbd0f43</citedby><cites>FETCH-LOGICAL-c493t-e8ba638e101205dc084b81f0010352b03812dde043f8c80f88528266a3dbd0f43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2578262502?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2578262502?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34658837$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peng, Zeyan</creatorcontrib><creatorcontrib>Zhou, Rui</creatorcontrib><creatorcontrib>Liu, Dong</creatorcontrib><creatorcontrib>Cui, Min</creatorcontrib><creatorcontrib>Yu, Ke</creatorcontrib><creatorcontrib>Yang, Hai</creatorcontrib><creatorcontrib>Li, Ling</creatorcontrib><creatorcontrib>Liu, Juan</creatorcontrib><creatorcontrib>Chen, Yang</creatorcontrib><creatorcontrib>Hong, Wenjuan</creatorcontrib><creatorcontrib>Huang, Jie</creatorcontrib><creatorcontrib>Wang, Congguo</creatorcontrib><creatorcontrib>Ma, Jingjing</creatorcontrib><creatorcontrib>Zhou, Huadong</creatorcontrib><title>Association Between Metabolic Syndrome and Mild Parkinsonian Signs Progression in the Elderly</title><title>Frontiers in aging neuroscience</title><addtitle>Front Aging Neurosci</addtitle><description>This study investigated the impact of metabolic syndrome on the progression from mild parkinsonian signs (MPS) to Parkinson's disease (PD).
A total of 1,563 participants with MPS completed 6 years of follow-up. The diagnosis of metabolic syndrome was made according to Adult Treatment Panel III of the National Cholesterol Education Program. The evaluations of MPS and PD were based on the motor portion of the Unified Parkinson's Disease Rating Scale. Cox proportional hazard models were used to identify the association between metabolic syndrome and PD conversion.
Of the 1,563 participants, 482 (30.8%) with MPS developed PD at the end of the follow-up. Metabolic syndrome (HR: 1.69, 95% CI: 1.29-2.03) was associated with the risk of PD conversion. Metabolic syndrome was associated with the progression of bradykinesia (HR: 1.85, 95% CI: 1.43-2.34), rigidity (HR: 1.36, 95% CI: 1.19-1.57), tremor (HR: 1.98, 95% CI: 1.73-2.32), and gait/balance impairment (HR: 1.66, 95% CI: 1.25-2.11). The effect of metabolic syndrome on the progression of bradykinesia and tremor was nearly two fold. Participants treated for two or three to four components of metabolic syndrome, including high blood pressure, high fasting plasma glucose, hypertriglyceridemia, and low HDL-C, had a lower risk of PD conversion.
Metabolic syndrome increased the risk of progression from MPS to PD. Participants treated for two or more components of metabolic syndrome had a lower risk of PD conversion.</description><subject>Aging</subject><subject>Alzheimer's disease</subject><subject>Balance</subject><subject>Basal ganglia</subject><subject>Blood pressure</subject><subject>Body mass index</subject><subject>Cardiovascular disease</subject><subject>Carotid arteries</subject><subject>Central nervous system diseases</subject><subject>Cholesterol</subject><subject>Cognitive ability</subject><subject>elderly</subject><subject>Fasting</subject><subject>Gait</subject><subject>Geriatric psychology</subject><subject>Glucose</subject><subject>Head injuries</subject><subject>High density lipoprotein</subject><subject>Hospitals</subject><subject>Hypertension</subject><subject>Hypertriglyceridemia</subject><subject>Metabolic syndrome</subject><subject>mild parkinsonian signs</subject><subject>Movement disorders</subject><subject>Neurodegenerative diseases</subject><subject>Neuroscience</subject><subject>Obesity</subject><subject>Older people</subject><subject>Parkinson's disease</subject><subject>progression</subject><subject>Risk factors</subject><subject>Tremor</subject><subject>Womens health</subject><issn>1663-4365</issn><issn>1663-4365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdksFO3DAQhqOqVUGUB-ilstRLL7u1PXEyuVSiCFokEEi0x8py7EnwNmtTO9tq356EpQjwZSz7n88z478o3gu-BMDmcxdM75eSS7GspUSoXhX7oqpgUUKlXj_Z7xWHOa_4tAA4V_i22IOyUohQ7xe_jnKO1pvRx8C-0viPKLALGk0bB2_Z9Ta4FNfETHDswg-OXZn024ccgzeBXfs-ZHaVYp8o5xnhAxtviJ0MjtKwfVe86cyQ6fAhHhQ_T09-HH9fnF9-Ozs-Ol_YsoFxQdiaCpAEF5IrZzmWLYqOc8FByZYDCukc8RI6tMg7RCVRVpUB1zrelXBQnO24LpqVvk1-bdJWR-P1_UFMvTZp9HYg7WzlulKoxk6ha0zbmlqoeTS1ANU0E-vLjnW7adfkLIUxmeEZ9PlN8De6j381KoEC52I-PQBS_LOhPOq1z5aGwQSKm6ylQgApaj6_9fGFdBU3KUyjmlT11KJUXE4qsVPZFHNO1D0WI7ievaDvvaBnL-idF6acD0-7eMz4__NwB66nsBA</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Peng, Zeyan</creator><creator>Zhou, Rui</creator><creator>Liu, Dong</creator><creator>Cui, Min</creator><creator>Yu, Ke</creator><creator>Yang, Hai</creator><creator>Li, Ling</creator><creator>Liu, Juan</creator><creator>Chen, Yang</creator><creator>Hong, Wenjuan</creator><creator>Huang, Jie</creator><creator>Wang, Congguo</creator><creator>Ma, Jingjing</creator><creator>Zhou, Huadong</creator><general>Frontiers Research Foundation</general><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2P</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20211001</creationdate><title>Association Between Metabolic Syndrome and Mild Parkinsonian Signs Progression in the Elderly</title><author>Peng, Zeyan ; Zhou, Rui ; Liu, Dong ; Cui, Min ; Yu, Ke ; Yang, Hai ; Li, Ling ; Liu, Juan ; Chen, Yang ; Hong, Wenjuan ; Huang, Jie ; Wang, Congguo ; Ma, Jingjing ; Zhou, Huadong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c493t-e8ba638e101205dc084b81f0010352b03812dde043f8c80f88528266a3dbd0f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aging</topic><topic>Alzheimer's disease</topic><topic>Balance</topic><topic>Basal ganglia</topic><topic>Blood pressure</topic><topic>Body mass index</topic><topic>Cardiovascular disease</topic><topic>Carotid arteries</topic><topic>Central nervous system diseases</topic><topic>Cholesterol</topic><topic>Cognitive ability</topic><topic>elderly</topic><topic>Fasting</topic><topic>Gait</topic><topic>Geriatric psychology</topic><topic>Glucose</topic><topic>Head injuries</topic><topic>High density lipoprotein</topic><topic>Hospitals</topic><topic>Hypertension</topic><topic>Hypertriglyceridemia</topic><topic>Metabolic syndrome</topic><topic>mild parkinsonian signs</topic><topic>Movement disorders</topic><topic>Neurodegenerative diseases</topic><topic>Neuroscience</topic><topic>Obesity</topic><topic>Older people</topic><topic>Parkinson's disease</topic><topic>progression</topic><topic>Risk factors</topic><topic>Tremor</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peng, Zeyan</creatorcontrib><creatorcontrib>Zhou, Rui</creatorcontrib><creatorcontrib>Liu, Dong</creatorcontrib><creatorcontrib>Cui, Min</creatorcontrib><creatorcontrib>Yu, Ke</creatorcontrib><creatorcontrib>Yang, Hai</creatorcontrib><creatorcontrib>Li, Ling</creatorcontrib><creatorcontrib>Liu, Juan</creatorcontrib><creatorcontrib>Chen, Yang</creatorcontrib><creatorcontrib>Hong, Wenjuan</creatorcontrib><creatorcontrib>Huang, Jie</creatorcontrib><creatorcontrib>Wang, Congguo</creatorcontrib><creatorcontrib>Ma, Jingjing</creatorcontrib><creatorcontrib>Zhou, Huadong</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Hospital Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni)</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Open Access Full Text</collection><jtitle>Frontiers in aging neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peng, Zeyan</au><au>Zhou, Rui</au><au>Liu, Dong</au><au>Cui, Min</au><au>Yu, Ke</au><au>Yang, Hai</au><au>Li, Ling</au><au>Liu, Juan</au><au>Chen, Yang</au><au>Hong, Wenjuan</au><au>Huang, Jie</au><au>Wang, Congguo</au><au>Ma, Jingjing</au><au>Zhou, Huadong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association Between Metabolic Syndrome and Mild Parkinsonian Signs Progression in the Elderly</atitle><jtitle>Frontiers in aging neuroscience</jtitle><addtitle>Front Aging Neurosci</addtitle><date>2021-10-01</date><risdate>2021</risdate><volume>13</volume><spage>722836</spage><epage>722836</epage><pages>722836-722836</pages><issn>1663-4365</issn><eissn>1663-4365</eissn><abstract>This study investigated the impact of metabolic syndrome on the progression from mild parkinsonian signs (MPS) to Parkinson's disease (PD).
A total of 1,563 participants with MPS completed 6 years of follow-up. The diagnosis of metabolic syndrome was made according to Adult Treatment Panel III of the National Cholesterol Education Program. The evaluations of MPS and PD were based on the motor portion of the Unified Parkinson's Disease Rating Scale. Cox proportional hazard models were used to identify the association between metabolic syndrome and PD conversion.
Of the 1,563 participants, 482 (30.8%) with MPS developed PD at the end of the follow-up. Metabolic syndrome (HR: 1.69, 95% CI: 1.29-2.03) was associated with the risk of PD conversion. Metabolic syndrome was associated with the progression of bradykinesia (HR: 1.85, 95% CI: 1.43-2.34), rigidity (HR: 1.36, 95% CI: 1.19-1.57), tremor (HR: 1.98, 95% CI: 1.73-2.32), and gait/balance impairment (HR: 1.66, 95% CI: 1.25-2.11). The effect of metabolic syndrome on the progression of bradykinesia and tremor was nearly two fold. Participants treated for two or three to four components of metabolic syndrome, including high blood pressure, high fasting plasma glucose, hypertriglyceridemia, and low HDL-C, had a lower risk of PD conversion.
Metabolic syndrome increased the risk of progression from MPS to PD. Participants treated for two or more components of metabolic syndrome had a lower risk of PD conversion.</abstract><cop>Switzerland</cop><pub>Frontiers Research Foundation</pub><pmid>34658837</pmid><doi>10.3389/fnagi.2021.722836</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1663-4365 |
ispartof | Frontiers in aging neuroscience, 2021-10, Vol.13, p.722836-722836 |
issn | 1663-4365 1663-4365 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_dc6df4159cdf4f9abba7150330713599 |
source | Publicly Available Content Database; PubMed Central; Coronavirus Research Database |
subjects | Aging Alzheimer's disease Balance Basal ganglia Blood pressure Body mass index Cardiovascular disease Carotid arteries Central nervous system diseases Cholesterol Cognitive ability elderly Fasting Gait Geriatric psychology Glucose Head injuries High density lipoprotein Hospitals Hypertension Hypertriglyceridemia Metabolic syndrome mild parkinsonian signs Movement disorders Neurodegenerative diseases Neuroscience Obesity Older people Parkinson's disease progression Risk factors Tremor Womens health |
title | Association Between Metabolic Syndrome and Mild Parkinsonian Signs Progression in the Elderly |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-03-09T21%3A54%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20Between%20Metabolic%20Syndrome%20and%20Mild%20Parkinsonian%20Signs%20Progression%20in%20the%20Elderly&rft.jtitle=Frontiers%20in%20aging%20neuroscience&rft.au=Peng,%20Zeyan&rft.date=2021-10-01&rft.volume=13&rft.spage=722836&rft.epage=722836&rft.pages=722836-722836&rft.issn=1663-4365&rft.eissn=1663-4365&rft_id=info:doi/10.3389/fnagi.2021.722836&rft_dat=%3Cproquest_doaj_%3E2578262502%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c493t-e8ba638e101205dc084b81f0010352b03812dde043f8c80f88528266a3dbd0f43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2578262502&rft_id=info:pmid/34658837&rfr_iscdi=true |